Relixir Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 10.50 Cr
as on 15-12-2024
- Paid Up Capital ₹ 10.50 Cr
as on 15-12-2024
- Company Age 13 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 26.81 Cr
as on 15-12-2024
- Revenue -43.65%
(FY 2022)
- Profit -57.40%
(FY 2022)
- Ebitda -34.93%
(FY 2022)
- Net Worth 8.24%
(FY 2022)
- Total Assets 1.02%
(FY 2022)
About Relixir Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.50 Cr and a paid-up capital of Rs 10.50 Cr.
The company has closed loans amounting to ₹26.81 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Relixir Pharmaceuticals Private Limited India is Navaratan Kakani as COMPANY SECRETARY. Anil Ramaya and Vinutha Mandula serve as directors at the Company.
- CIN/LLPIN
U24100TG2011PTC072584
- Company No.
072584
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Feb 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Relixir Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Navaratan Kakani | Company Secretary | 01-Feb-2019 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Ramaya  | Director | 14-Feb-2011 | Current |
Vinutha Mandula  | Director | 10-Oct-2014 | Current |
Financial Performance and Corporate Structure Insights of Relixir Pharmaceuticals.
Relixir Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 43.65% decrease. The company also saw a substantial fall in profitability, with a 57.4% decrease in profit. The company's net worth moved up by a moderate rise of 8.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Relixir Pharmaceuticals?
In 2022, Relixir Pharmaceuticals had a promoter holding of 95.80% and a public holding of 4.20%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Novocura Tech Health Services Private LimitedActive 7 years 10 monthsNavaratan Kakani is a mutual person
- Netpixel Software Solutions India Private LimitedActive 16 years 8 months
Anil Ramaya is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Apr 2022 | ₹1.45 Cr | Satisfied |
Others Creation Date: 23 Nov 2020 | ₹7.00 M | Satisfied |
Others Creation Date: 16 Aug 2017 | ₹24.66 Cr | Satisfied |
How Many Employees Work at Relixir Pharmaceuticals?
Relixir Pharmaceuticals has a workforce of 60 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Relixir Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Relixir Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
